GOSS Latest Press Releases

-- November 10, 2026 --

Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update Business Wire 4:01 PM

-- September 23, 2026 --

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension Business Wire 4:01 PM

-- September 16, 2026 --

Gossamer Bio Appoints Greg Ciongoli to Board of Directors Business Wire 4:01 PM

-- September 11, 2026 --

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split Business Wire 8:00 AM

-- September 9, 2026 --

Gossamer Bio Announces 1-for-80 Reverse Stock Split Business Wire 9:00 AM

-- September 4, 2026 --

Gossamer Bio to Present at Cantor Global Healthcare Conference Business Wire 8:00 AM

-- August 21, 2026 --

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval Business Wire 8:00 AM

-- August 13, 2026 --

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update Business Wire 4:01 PM

-- August 10, 2026 --

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm PRNewswire 9:24 AM

-- July 27, 2026 --

Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update Business Wire 7:00 AM

-- July 1, 2026 --

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants Business Wire 9:00 AM

-- June 17, 2026 --

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes Business Wire 8:00 AM

Market Data Delayed 15 Minutes